Regeneron Pharmaceuticals (REGN) Revenue — Quarter Ended Jun 30, 2024
Revenue for the quarter increased compared to the prior quarter and also rose relative to the same quarter last year. The sequential growth reversed a decline in the preceding quarter.
Key takeaway
Quarter ended Jun 30, 2024 · FY2024 Q2
Revenue for the quarter increased compared to the prior quarter and also rose relative to the same quarter last year. The sequential growth reversed a decline in the preceding quarter.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3.5B
Revenue reported for this quarter.
Quarter-over-quarter
+12.8%
Change from the immediately preceding quarter.
Year-over-year
+12.3%
Change from the comparable year-ago quarter.
Trailing four quarters
$13.5B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2023 | $3.4B | +14.5% |
| Dec 31, 2023 | $3.4B | +0.6% |
| Mar 31, 2024 | $3.1B | -0.5% |
| Jun 30, 2024 | $3.5B | +12.3% |
Revenue performance
The reported revenue direction was upward, marking a recovery from the prior quarter's decrease.
Quarterly comparison
Compared with the immediately preceding quarter, revenue increased. Versus the same quarter one year earlier, revenue also showed an increase.
What to watch
Monitor whether the sequential growth can be sustained in the coming quarters.